⚠ EN DIRECT — European Consumer Safety Watch 💊 Médicaments: 16 au cours des 7 derniers jours 🍎 Alimentation: 193 au cours des 7 derniers jours 🧸 Produits: 48 au cours des 7 derniers jours 🟢 Surveillance: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Dernière récupération: il y a 3 heures ⚠ EN DIRECT — European Consumer Safety Watch 💊 Médicaments: 16 au cours des 7 derniers jours 🍎 Alimentation: 193 au cours des 7 derniers jours 🧸 Produits: 48 au cours des 7 derniers jours 🟢 Surveillance: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Dernière récupération: il y a 3 heures
🛡️ EUSW
🇫🇷
💊

Exjade

deferasirox
bêta-thalassémie ; surcharge en fer
✅ Autorisé
Aucune alerte active
Ce médicament ne fait l'objet ni de pénuries en cours, ni de lettres de sécurité, ni de rappels.

À quoi ça sert

Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older. Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged two to five years; in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged two years and older; in patients with other anaemias aged two years and older. Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.

⚠️ Sécurité des patients

No

⚠️ Nous agrégeons des avis officiels. Nous ne donnons pas d'avis médical. Pour toute décision médicale ou juridique, consultez l'agence source et un professionnel qualifié.